Yi Su
State Key Laboratory Of Drug Research
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Design, Synthesis and Biological Evaluation of Novel SN38 Based Albumin-Binding Peptide-Drug Conjugates in Pancreatic Ductal Adenocarcinoma.
Journal: Pharmaceutics
Published: May 28, 2026
Long-circulating enzyme-activated HSP90-targeted camptothecin derivatives.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: November 19, 2024
Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
Journal: European journal of medicinal chemistry
Published: October 28, 2023
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Journal: Molecular cancer
Published: August 19, 2023
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.
Journal: European journal of medicinal chemistry
Published: June 05, 2023
Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.
Journal: Acta pharmaceutica Sinica. B
Published: May 14, 2023
ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK.
Journal: Frontiers in pharmacology
Published: October 15, 2022
Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression.
Journal: Signal transduction and targeted therapy
Published: January 04, 2022
Quantum Chemical and Kinetic Studies of N2O Formation during Interaction between Char(N) and NO: Influence of Oxygen, Active Sites, and Nitrogen Status.
Journal: The journal of physical chemistry. A
Published: October 12, 2021
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Journal: Molecular cancer
Published: August 18, 2021
Author Correction: G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
Journal: Nature communications
Published: July 26, 2020
Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
Journal: Bioorganic & medicinal chemistry letters
Published: January 07, 2020
Last Updated: 09/26/2026